Total Payments
$1.6M
2024 Payments
$338,288
Companies
33
Transactions
1,010
Payment Breakdown by Category
Consulting$894,336 (56.7%)
Other$386,379 (24.5%)
Travel$141,626 (9.0%)
Research$141,365 (9.0%)
Food & Beverage$13,846 (0.9%)
Education$866.24 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $894,336 | 271 | 56.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $323,564 | 90 | 20.5% |
| Travel and Lodging | $141,626 | 241 | 9.0% |
| Unspecified | $141,365 | 133 | 9.0% |
| Honoraria | $47,915 | 13 | 3.0% |
| Food and Beverage | $13,846 | 259 | 0.9% |
| Grant | $10,000 | 1 | 0.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,900 | 1 | 0.3% |
| Education | $866.24 | 1 | 0.1% |
Payments by Type
General
$1.4M
877 transactions
Research
$141,365
133 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $655,353 | 326 | $0 (2024) |
| ABBVIE INC. | $404,395 | 342 | $0 (2024) |
| Eli Lilly and Company | $134,859 | 102 | $0 (2024) |
| Janssen Biotech, Inc. | $85,656 | 82 | $0 (2024) |
| Takeda Pharmaceuticals International, Inc. | $44,196 | 6 | $0 (2019) |
| Celgene Corporation | $29,963 | 10 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $25,896 | 17 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $23,357 | 7 | $0 (2024) |
| WHITEHALL INTERNATIONAL INC | $19,572 | 3 | $0 (2021) |
| Merck Sharp & Dohme LLC | $18,537 | 11 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $338,288 | 182 | PFIZER INC. ($146,064) |
| 2023 | $280,180 | 165 | PFIZER INC. ($109,280) |
| 2022 | $183,326 | 146 | ABBVIE INC. ($80,040) |
| 2021 | $152,885 | 75 | PFIZER INC. ($51,340) |
| 2020 | $145,907 | 60 | PFIZER INC. ($70,642) |
| 2019 | $129,902 | 112 | PFIZER INC. ($74,709) |
| 2018 | $170,761 | 131 | PFIZER INC. ($68,730) |
| 2017 | $177,170 | 139 | PFIZER INC. ($72,298) |
All Payment Transactions
1,010 individual payment records from CMS Open Payments — Page 1 of 41
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $2,125.00 | General |
| Category: Immunology | ||||||
| 12/17/2024 | ABBVIE INC. | SKYRIZI (Biological) | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Consulting Fee | Cash or cash equivalent | $9,075.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/16/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,050.00 | General |
| 12/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,550.00 | General |
| Category: Immunology | ||||||
| 12/07/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $38.42 | General |
| Category: Immunology | ||||||
| 12/05/2024 | Eli Lilly and Company | OMVOH (Drug) | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| Category: Immunology | ||||||
| 12/05/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 12/04/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: XELJANZ CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/03/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 12/03/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 11/29/2024 | Celltrion, Inc. | — | Honoraria | Cash or cash equivalent | $3,990.00 | General |
| 11/26/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $949.04 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/18/2024 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $800.00 | General |
| 11/13/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Consulting Fee | Cash or cash equivalent | $2,445.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/09/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $9,954.00 | General |
| 11/06/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $3,200.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 11/06/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $601.99 | General |
| 11/06/2024 | Eli Lilly and Company | — | Travel and Lodging | Cash or cash equivalent | $31.99 | General |
| 10/29/2024 | PFIZER INC. | VELSIPITY (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: VELSIPITY CLINICAL PUBLICATION PROGRAM • Category: INFLAMMATION;PAIN | ||||||
| 10/29/2024 | PFIZER INC. | VELSIPITY (Drug) | Travel and Lodging | In-kind items and services | $343.26 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 10/29/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $9.32 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: XELJANZ CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 10/28/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $825.00 | General |
| 10/27/2024 | PFIZER INC. | XELJANZ (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: XELJANZ CLINICAL PUBLICATION PROGRAM • Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| TOFACITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $61,410 | 56 |
| ETRASIMOD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $47,130 | 48 |
| TOFACITINIB IBD CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $16,820 | 11 |
| VELSIPITY CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $10,100 | 10 |
| Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol | UCB, Inc. | $2,300 | 1 |
| XELJANZ CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $2,210 | 3 |
| Pharmacovigilance data on pregnancy outcomes in women with Crohns disease exposed to certolizumab pegol | UCB, Inc. | $420.00 | 1 |
| Pharmacovigilance data on pregnancy outcomes in women with Crohn disease exposed to certolizumab pegol | UCB, Inc. | $400.00 | 1 |
About Dr. Marla Dubinsky, M.D
Dr. Marla Dubinsky, M.D is a Specialist healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790741718.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marla Dubinsky, M.D has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $338,288 received in 2024. These payments were reported across 1,010 transactions from 33 companies. The most common payment nature is "Consulting Fee" ($894,336).
Ad
Practice Information
- Specialty Specialist
- Location New York, NY
- Active Since 04/26/2006
- Last Updated 03/17/2015
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1790741718
Products in Payments
- XELJANZ (Drug) $396,603
- VELSIPITY (Drug) $184,788
- SKYRIZI (Biological) $123,017
- RINVOQ (Biological) $120,839
- Entyvio (Biological) $60,480
- Humira (Biological) $56,825
- TREMFYA (Drug) $51,446
- STELARA (Biological) $36,272
- ZEPOSIA (Drug) $25,095
- INFLECTRA (Biological) $17,438
- HUMIRA (Biological) $16,994
- Non-Covered Product (Drug) $16,497
- REMICADE (Biological) $10,521
- ZYMFENTRA (Biological) $10,083
- Cimzia (Drug) $8,973
- UCERIS (Drug) $8,344
- SIMPONI (Biological) $8,146
- OMVOH (Drug) $7,600
- ENTYVIO (Biological) $4,976
- Otezla (Drug) $122.52
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in New York
Dr. Eric Rose, M.d, M.D
Specialist — Payments: $4.9M
Specialist $4.9M
Dr. Baron Lonner, M.d, M.D
Specialist — Payments: $2.9M
Specialist $2.9M
Dr. Richard Spaide, Md, MD
Specialist — Payments: $1.7M
Specialist $1.7M
Mrs. Naomi Nakao, M.d, M.D
Specialist — Payments: $1.1M
Specialist $1.1M
Dr. Janice Dutcher, M.d, M.D
Specialist — Payments: $994,054
Specialist $994,054
Grace Hyun, Md, MD
Specialist — Payments: $851,352
Specialist $851,352